Marshall Financial Group LLC Sells 3,963 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Marshall Financial Group LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 80.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 960 shares of the pharmaceutical company’s stock after selling 3,963 shares during the quarter. Marshall Financial Group LLC’s holdings in Vertex Pharmaceuticals were worth $387,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth $25,000. Highline Wealth Partners LLC purchased a new stake in Vertex Pharmaceuticals in the third quarter valued at about $27,000. Dunhill Financial LLC boosted its holdings in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares in the last quarter. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter worth about $33,000. Finally, Truvestments Capital LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $35,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

VRTX has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday. Truist Financial cut their target price on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. HC Wainwright cut their price objective on Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a report on Friday, December 20th. Finally, Citigroup began coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $575.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $494.84.

Vertex Pharmaceuticals Trading Down 0.0 %

Shares of NASDAQ VRTX opened at $439.62 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The firm has a fifty day moving average of $435.36 and a 200 day moving average of $464.51. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.67 earnings per share. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.